Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.
Biotechs are sprinting to the IPO queue.
In the industry’s fourth IPO filing in two weeks, Braveheart Bio is seeking a Nasdaq listing to fuel …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s…
Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug…
Kardigan launches $320M IPO to fund three late-stage cardio drugs as biotech listings hit a post-pandemic high.
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical…
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most…
From the co-founders of Turning Point, BlossomHill Therapeutics filed its IPO paperwork as it tests a macrocyclic small molecule…
